Physician profile
Xin Wang
NPI 1528051257
$4,298.95
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,184 · 2020: $1,067 · 2021: $1,033 · 2023: $14.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $412.24 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $397.51 | 2019-2021 | |
| Emd Serono, INC. | $267.96 | 2019-2020 | |
| Ucb, INC. | $206.59 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $205.37 | 2019-2021 | |
| Genentech USA, INC. | $196.74 | 2019-2021 | |
| Amgen INC. | $186.22 | 2019-2021 | |
| Biogen, INC. | $166.34 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $160.71 | 2019-2021 | |
| Genzyme Corporation | $159.35 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $154.57 | 2019-2021 | |
| Eisai INC. | $149.59 | 2019-2021 | |
| Kyowa Kirin, INC. | $144.12 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $138.59 | 2019-2021 | |
| Adamas Pharmaceuticals, INC. | $123.44 | 2019-2021 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $116.55 | 2019-2020 | |
| Abbvie INC. | $99.94 | 2021 | |
| Upsher-Smith Laboratories LLC | $93.03 | 2019-2021 | |
| Lundbeck LLC | $79.13 | 2020-2021 | |
| Akcea Therapeutics, INC. | $76.40 | 2019 | |
| Amneal Pharmaceuticals LLC | $76.16 | 2019-2021 | |
| Assertio Therapeutics, INC. | $69.18 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $61.90 | 2021 | |
| Lilly USA, LLC | $61.53 | 2020-2021 | |
| Csl Behring | $61.44 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $61.08 | 2020-2021 | |
| Neurelis, INC. | $43.77 | 2020-2021 | |
| Acorda Therapeutics, INC | $39.22 | 2019 | |
| Celgene Corporation | $39.11 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $32.55 | 2020 | |
| Mallinckrodt Enterprises LLC | $32.12 | 2019 | |
| Avanir Pharmaceuticals, INC. | $31.32 | 2019-2020 | |
| Tersera Therapeutics LLC | $30.00 | 2019 | |
| Neurocrine Biosciences, INC. | $24.43 | 2020 | |
| Mallinckrodt Hospital Products INC. | $22.31 | 2020 | |
| Tanabe Pharma America, INC. | $17.88 | 2019 | |
| Alnylam Pharmaceuticals INC. | $15.49 | 2019 | |
| Strongbridge US INC. | $15.31 | 2020 | |
| Pfizer INC. | $15.04 | 2019 | |
| Argenx US, INC. | $14.72 | 2023 | Vyvgart |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Xin Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.